Idarubicin
Small molecule targets TOP2A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | IDAMYCIN | — | 1990-09-27 | fda.gov ↗ |
Trials 160 · started per year
Also used as a comparator or background therapy in 141 trials
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2006-11-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Agreement With Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin tevapharm.com ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 305 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Idarubicin | “Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8,...” NCT06211452 ↗296“* FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine...” NCT06387069 ↗ “Standard Chemotherapy includes IA(Idarubicin combined with Cytarabine) or DA(Daunorubicin combined with Cytarabine). IDA is given by venous drip daily at 12mg/m2, or DNR is...” NCT06810791 ↗ “R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion...” NCT02657785 ↗ “R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in...” NCT02836158 ↗ “To further intensify anthracycline dosage without increasing cardiotoxicity, we compared potentially less cardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a...” PMID 23704089 ↗ May 2013 “Resistant participants will receive a second induction with inotuzumab for B-cell precursor ALL or with FLAG-Ida (fludarabine, cytarabine, idarubicin and granulocyte colony...” NCT07443592 ↗ “Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day...” NCT03446638 ↗ “Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant...” NCT00559221 ↗ “A Phase I Study Using Bortezomib (Velcade, Formerly Known as PS-341) With Weekly Idarubicin for the Treatment of Elderly (>/= 60 Years) and Relapsed Patients With Acute...” NCT00382954 ↗ “For FLT3/IDH1 wild-type participants who are eligible for chemotherapy, Anthracycline: Daunorubicin (DNR) 45 mg/m² per day on Days 1-3, or Idarubicin (IDA) 6 mg/m² per day on Days 1-3.” NCT07548710 ↗ “High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida).” NCT02920008 ↗ “Drugs used in chemotherapy, such as arsenic trioxide, cytarabine, and idarubicin, work in different ways to stop cancer cells from dividing so they stop growing or die.” NCT00093483 ↗ “Specified in the protocol were vincristine/doxorubicin/dexamethasone (VAD), idarubicin/dexamethasone (ID) and cyclophosphamide/doxorubicin/dexamethasone (CAD).” NCT02288741 ↗ “Idarubicin is designed to cause breaks in DNA (the genetic material of cells) of cancer cells and interfere with their growth and development.” NCT01025154 ↗ “Daunorubicin or idarubicin will only be used during induction in patients \<65 with presenting white blood cell count (WBC) ≥ 10 x 10\^9/L.” NCT04687176 ↗ “Subjects on Ara-C±IDA chemotherapy received cytarabine 1\~3 g/m\^2 daily by IV for 3 days and idarubicin 10 mg/m\^2 daily by IV for 3 days.” NCT05586074 ↗ “Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia” NCT00086099 ↗ “Resistant patients will receive a second induction with fludarabine, Ara-C, G-Colony-Stimulating Factor (G-CSF) and idarubicin (FLAG-IDA).” NCT04179929 ↗ “Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)” NCT02323022 ↗ “high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)” NCT01587430 ↗ “Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.” NCT03512197 ↗ “Induction therapy included idarubicin 8 mg/m2 on days 1 to 5, cytarabine 100 mg/m2 on days 1 to 7, and lomustine 200 mg/m2 on day 1.” PMID 28129526 ↗ Oct 2016 “Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin or idarubicin).” NCT06578247 ↗ “Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.” NCT06226571 ↗ “The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7.” NCT01496547 ↗ “alternating cyclophosphamide, vincristine and idarubicin alternating with another 3 cycles of carboplatin and etoposide” NCT03475121 ↗ “The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3.” NCT02665143 ↗ “intensive chemotherapy(cytarabine with idarubicin or daunorubicin), which short as"7+3 induction regimen"” NCT06746519 ↗ “oral bcl-2 inhibitor plus IM2(Ifosfamide plus Mitoxantrone or Idarubicin plus methotrexate) chemotherapy” NCT05576532 ↗ “Cytarabine 100mg/m² days 1-7 Idarubicin 12mg/m² days 1-3 Avapritinib orally on days 8-21 (28-day cycle)” NCT07028073 ↗ “Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 of treatment by slow intravenous infusion (20 minutes).” NCT00465933 ↗ “Idarubicin (IDA): 10mg/m\^2/d (age \<60 years old) or 6mg/m\^2/d on days 1-3, intravenously (IV).” NCT06643962 ↗ “Idarubicin (IDA) 10mg/㎡ for d1-3 , Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5)” NCT06529250 ↗ “idarubicin (intravenous infusion 10 mg/m2 per day on days 2-4 in up to two 28-day cycles)” PMID 31175001 ↗ Jun 2019 “Either daunorubicin or idarubicin was administered via slow intravenous (IV) push” NCT05020665 ↗ “Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia” NCT01794702 ↗ “idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14” NCT03985007 ↗ “strategy based on idarubicin to achieve a more effective antitumor effect” NCT02870010 ↗ “Idarubicin (Idarubicin): 10-12mg/m2 on days 1 to 3; intravenous infusion” NCT06232694 ↗ “The MTD of idarubicin was 20 mg after two chemolipiodolisation sessions.” PMID 29427728 ↗ Feb 2018 “Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6.” NCT01018069 ↗ “IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5” NCT00909168 ↗ “idarubicin hydrochloride,10 mg/d, IV, on day 1, 3, and 5.” NCT04541277 ↗ “Idarubicin 5mg/m2 i.v. daily on days 3, 4 and 5 (3 doses)” NCT02272478 ↗ “Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4.” NCT01698879 ↗ “fludarabine - cytarabine - idarubicin - G-CSF (FLAG-IDA)” NCT06713837 ↗ “Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim” NCT00893399 ↗ “Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3” NCT00931138 ↗ “Intravenous Idarubicin (Ida): 6 mg/m²/day on days 1-3” NCT07108530 ↗ “idarubicin (8 mg/m²) infusion (15-30 min) for 3 days” NCT02172872 ↗ “daunorubicin or idarubicin, Rubidomycin or Idamycin” NCT03760445 ↗ “Daunorubicin/ Cytarabine or Idarubicin/Cytarabine” NCT04676243 ↗ “Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily.” NCT01987297 ↗ “Idarubicin (IDA): 8 mg/m², days 1, 8, 15, 22.” NCT07059156 ↗ “I (Idarubicin): 8 mg/m²/day on days 1 and 8.” NCT06930105 ↗ “Fludarabine, Cytarabine, Idarubicin, G-CSF” NCT03257241 ↗ “Idarubicin 10 mg/m2 on days 1, 8, (15~17)” NCT05827549 ↗ “Idarubicin: 8-12 mg/m\^2 on days 1 to 3” NCT07514936 ↗ “idarubicin (8 mg/m2/d (IV) for 5 days)” NCT00925873 ↗ “1. Idarubicin (8-10 mg/m2) for 3 days.” NCT07512700 ↗ “Idarubicin 8 mg/m², intravenous, day 1” NCT07564453 ↗ “with or without doxorubicin/idarubicin” NCT04770207 ↗ “Idarubicin (8-10 mg/m2) for 3 days .” NCT06068621 ↗ “Idarubicin (8-10 mg/m2) for 3 days .” NCT06928376 ↗ “Hydroxyurea, Idarubicin, Ifosfamide” NCT02788201 ↗ “Drug: idarubicin, intravenously” NCT06652685 ↗ “idarubicin 10 mg/m² days 1 \& 3” NCT02013167 ↗ “Idarubicin 12mg/m2 IV at D1” NCT03599960 ↗ “Idarubicin: 15mg/m2/d” NCT01873807 ↗ “Idarubicin” NCT02277847 ↗ “idarubicin” NCT06451861 ↗ “Idarubicin” NCT02665065 ↗ |
| Known as | 4-Demethoxydaunomycin | “4-Demethoxydaunomycin” NCT00801489 ↗ |
| Known as | 4-demethoxydaunorubicin | “4-demethoxydaunorubicin” NCT00801489 ↗ |
| Known as | IDA | “The study included 727 older patients with AML (median age, 67 years) treated in two idarubicin (IDA) versus daunorubicin (DNR) Acute Leukemia French Association trials.” PMID 23248249 ↗ Dec 201211“We report on a Phase 2 clinical trial using the novel combination of 2-chlorodeoxyadenosine (2-CDA) (8 mg/m² per d x 5 d) plus idarubicin (Ida) (10 mg/m² per d x 3 d).” PMID 22512017 ↗ Mar 2012 “Idarubicin (IDA) 10mg/㎡ for d1-3 , Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5)” NCT06529250 ↗ “Continuous infusion of idarubicin (IDA) over 48 hours on days -12 and -11” NCT00002989 ↗ “Intravenous Idarubicin (Ida): 6 mg/m²/day on days 1-3” NCT07108530 ↗ “Idarubicin (IDA): 8 mg/m², days 1, 8, 15, 22.” NCT07059156 ↗ “idarubicin (IDA) IV on days 3 and 4” NCT00002771 ↗ “IDA Idarubicin, NSC-256439” NCT00002565 ↗ “IDA Idarubicin, NSC-256439” NCT00002549 ↗ “Drug: Idarubicin（IDA）” NCT07078591 ↗ “idarubicin (IDA)” NCT00002701 ↗ “Idarubicin（IDA）” NCT02671708 ↗ |
| Known as | Idamycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗ |
| Known as | Idamycin pfs | ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗ |
| Known as | Idarubicin hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗ |
| Known as | Idarubicin Hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05955261 ↗ |
| Known as | Idarubicin Hydrochloride for Injection | “Drug: Idarubicin Hydrochloride for Injection” NCT05280444 ↗1“Drug: Idarubicin Hydrochloride for Injection” NCT05053386 ↗ |
| Known as | Idarubicin hydrochloride pfs | ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗ |
| Known as | Idarubicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗ |
| Known as | Idarubicine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04087967 ↗ |
| Known as | IMI 30 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1117 ↗ |
| Known as | NSC-256439 | “IDA Idarubicin, NSC-256439” NCT00002565 ↗ |
| Known as | Zavedos | “Idarubicin (Zavedos®) as the reconstituted solution, will be administered slowly by the intravenous route over 60 minutes at 10 mg/m²of body-surface area on day 8 of...” NCT01342692 ↗4“Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization Microspheres (DC Bead™) Loaded With Idarubicin (Zavedos®): Phase 1 Study” NCT02870010 ↗ “Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study” NCT02028949 ↗ “administration of Idarubicin (Zavedos®, Pfizer) mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet) in the hepatic artery.” NCT04178642 ↗ |
| Action | Inhibit | “DNA topoisomerase II alpha inhibitor” CHEMBL1117 ↗1“to stop DNA from repairing itself” NCT00542971 ↗ |
| Modality | Small molecule | “oral anthracycline” NCT01958996 ↗ |
| Route | Intravenous | “idarubicin IV on days 3-5” NCT00002517 ↗ |
| Target | TOP2A | “DNA topoisomerase II alpha inhibitor” CHEMBL1117 ↗ |